THC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
THC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Tenet Healthcare's Future 3-5Y Total Revenue Growth Rate is 2.77.
For the Medical Care Facilities subindustry, Tenet Healthcare's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Tenet Healthcare's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Tenet Healthcare's Future 3-5Y Total Revenue Growth Rate falls into.
Tenet Healthcare (NYSE:THC) Future 3-5Y Total Revenue Growth Rate Explanation
Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Tenet Healthcare's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Lisa Y Foo | officer: EVP, Commercial Ops | 14201 DALLAS PARKWAY, DALLAS TX 75254 |
R. Scott Ramsey | officer: Principal Accounting Officer | 1445 ROSS AVENUE, SUITE 1400, DALLAS TX 75202 |
Richard W Fisher | director | |
Paola M Arbour | officer: EVP, Chief Information Officer | 14201 DALLAS PARKWAY, DALLAS TX 75254 |
Saumya Sutaria | officer: Chief Operating Officer | 14201 DALLAS PARKWAY, DALLAS TX 75254 |
Meghan Fitzgerald | director | C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511 |
J Robert Kerrey | director | NEW SCHOOL UNIVERSITY, 66 W. 12TH STREET, NEW YORK NY 10036 |
Christopher S. Lynch | director | 8200 JONES BRANCH DRIVE, MCLEAN VA 22102 |
Nadja West | director | 1915 REXFORD ROAD, CHARLOTTE NC 28211 |
Thomas W Arnst | officer: EVP, Chief Admin. Officer & GC | 14201 DALLAS PARKWAY, DALLAS TX 75254 |
Richard J Mark | director | 1901 CHOUTEAU AVENUE MC-1310, ST. LOUIS MO 63103 |
Roy Blunt | director | 2702 LOVE FIELD DRIVE, HDQ 4GC, DALLAS TX 75235 |
Stephen H Rusckowski | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Tammy Romo | director | C/O SOUTHWEST AIRINES CO., 2702 LOVE FIELD DR., DALLAS TX 75235 |
Daniel J Cancelmi | officer: Principal Accounting Officer | 13737 NOEL ROAD, SUITE 100, DALLAS TX 75240 |
From GuruFocus
By GuruFocus News • 11-13-2024
By Business Wire • 08-05-2024
By GuruFocus Research • 08-15-2024
By GuruFocus Research • 07-25-2024
By GuruFocus News • 11-01-2024
By GuruFocus News • 11-02-2024
By Business Wire • 07-24-2024
By GuruFocus Research • 07-25-2024
By GuruFocus News • 11-14-2024
By Business Wire • 06-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.